Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.
Identifieur interne : 002590 ( PubMed/Curation ); précédent : 002589; suivant : 002591Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.
Auteurs : Yanbin Wang [République populaire de Chine] ; Zhaorui Chang ; Jing Ouyang ; Haiyan Wei ; Renquan Yang ; Yangong Chao ; Jianguo Qu ; Jianwei Wang ; Tao HungSource :
- DNA and cell biology [ 1044-5498 ] ; 2005.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (sang), Escherichia coli (génétique), Escherichia coli (métabolisme), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Humains, Immunoglobuline G (sang), Protéines de l'enveloppe virale (immunologie), Protéines nucléocapside (immunologie), Protéines recombinantes (immunologie), Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (immunologie), Virus du SRAS (immunologie).
- MESH :
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Escherichia coli.
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines nucléocapside, Protéines recombinantes, Syndrome respiratoire aigu sévère, Virus du SRAS.
- métabolisme : Escherichia coli.
- sang : Anticorps antiviraux, Immunoglobuline G.
- Glycoprotéine de spicule des coronavirus, Humains.
English descriptors
- KwdEn :
- Antibodies, Viral (blood), Escherichia coli (genetics), Escherichia coli (metabolism), Humans, Immunoglobulin G (blood), Membrane Glycoproteins (immunology), Nucleocapsid Proteins (immunology), Recombinant Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (immunology).
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- diagnosis : Severe Acute Respiratory Syndrome.
- genetics : Escherichia coli.
- chemical , immunology : Membrane Glycoproteins, Nucleocapsid Proteins, Recombinant Proteins, SARS Virus, Severe Acute Respiratory Syndrome, Viral Envelope Proteins.
- metabolism : Escherichia coli.
- Humans, Spike Glycoprotein, Coronavirus.
Abstract
To evaluate humoral immunity against the SARS-associated coronavirus (SARS-CoV), we studied the profiles of IgG antibodies to the nucleocapsid (N) and spike (S) proteins of SARS-CoV. Serum specimens from 10 SARS patients were analyzed by Western blotting and an enzyme-linked immunosorbent assay (ELISA) using purified recombinant N and truncated S (S1, S2, and S3) proteins as antigens. Western blotting results demonstrated that 100% of the SARS patients tested positive for N protein-specific antibodies, 50% for S1 protein-specific antibodies, 30% for S2 protein-specific antibodies, and 70% for S3 protein-specific antibodies. The ELISA results, which showed positive rates of IgG reactivity against recombinant proteins N, S1, S2, and S3, were, respectively, 28.57, 14.29, 14.29, and 14.29% at week 1, 77.78, 55.56, 44.44, and 66.67% at week 2, 100, 75, 75, and 87.5% at week 3, and 100, 77.78, 77.78, and 88.89% after 3 weeks. The average titers of IgG against recombinant proteins N, S1, S2, and S3 were, respectively, 691, 56, 38, and 84 after 3 weeks. These results suggest that the recombinant proteins N and S3 are potentially useful antigens for a serological diagnosis of SARS. In consideration of possible cross-reactivity among N proteins of SARS-CoV and other coronaviruses, immunoassays using recombinant N protein in combination with S3 as antigens might improve the specificity of SARS diagnoses.
DOI: 10.1089/dna.2005.24.521
PubMed: 16101351
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002590
Links to Exploration step
pubmed:16101351Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.</title><author><name sortKey="Wang, Yanbin" sort="Wang, Yanbin" uniqKey="Wang Y" first="Yanbin" last="Wang">Yanbin Wang</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Chang, Zhaorui" sort="Chang, Zhaorui" uniqKey="Chang Z" first="Zhaorui" last="Chang">Zhaorui Chang</name></author><author><name sortKey="Ouyang, Jing" sort="Ouyang, Jing" uniqKey="Ouyang J" first="Jing" last="Ouyang">Jing Ouyang</name></author><author><name sortKey="Wei, Haiyan" sort="Wei, Haiyan" uniqKey="Wei H" first="Haiyan" last="Wei">Haiyan Wei</name></author><author><name sortKey="Yang, Renquan" sort="Yang, Renquan" uniqKey="Yang R" first="Renquan" last="Yang">Renquan Yang</name></author><author><name sortKey="Chao, Yangong" sort="Chao, Yangong" uniqKey="Chao Y" first="Yangong" last="Chao">Yangong Chao</name></author><author><name sortKey="Qu, Jianguo" sort="Qu, Jianguo" uniqKey="Qu J" first="Jianguo" last="Qu">Jianguo Qu</name></author><author><name sortKey="Wang, Jianwei" sort="Wang, Jianwei" uniqKey="Wang J" first="Jianwei" last="Wang">Jianwei Wang</name></author><author><name sortKey="Hung, Tao" sort="Hung, Tao" uniqKey="Hung T" first="Tao" last="Hung">Tao Hung</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16101351</idno><idno type="pmid">16101351</idno><idno type="doi">10.1089/dna.2005.24.521</idno><idno type="wicri:Area/PubMed/Corpus">002590</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002590</idno><idno type="wicri:Area/PubMed/Curation">002590</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002590</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.</title><author><name sortKey="Wang, Yanbin" sort="Wang, Yanbin" uniqKey="Wang Y" first="Yanbin" last="Wang">Yanbin Wang</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Chang, Zhaorui" sort="Chang, Zhaorui" uniqKey="Chang Z" first="Zhaorui" last="Chang">Zhaorui Chang</name></author><author><name sortKey="Ouyang, Jing" sort="Ouyang, Jing" uniqKey="Ouyang J" first="Jing" last="Ouyang">Jing Ouyang</name></author><author><name sortKey="Wei, Haiyan" sort="Wei, Haiyan" uniqKey="Wei H" first="Haiyan" last="Wei">Haiyan Wei</name></author><author><name sortKey="Yang, Renquan" sort="Yang, Renquan" uniqKey="Yang R" first="Renquan" last="Yang">Renquan Yang</name></author><author><name sortKey="Chao, Yangong" sort="Chao, Yangong" uniqKey="Chao Y" first="Yangong" last="Chao">Yangong Chao</name></author><author><name sortKey="Qu, Jianguo" sort="Qu, Jianguo" uniqKey="Qu J" first="Jianguo" last="Qu">Jianguo Qu</name></author><author><name sortKey="Wang, Jianwei" sort="Wang, Jianwei" uniqKey="Wang J" first="Jianwei" last="Wang">Jianwei Wang</name></author><author><name sortKey="Hung, Tao" sort="Hung, Tao" uniqKey="Hung T" first="Tao" last="Hung">Tao Hung</name></author></analytic><series><title level="j">DNA and cell biology</title><idno type="ISSN">1044-5498</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (blood)</term><term>Escherichia coli (genetics)</term><term>Escherichia coli (metabolism)</term><term>Humans</term><term>Immunoglobulin G (blood)</term><term>Membrane Glycoproteins (immunology)</term><term>Nucleocapsid Proteins (immunology)</term><term>Recombinant Proteins (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (diagnosis)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (sang)</term><term>Escherichia coli (génétique)</term><term>Escherichia coli (métabolisme)</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Humains</term><term>Immunoglobuline G (sang)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines nucléocapside (immunologie)</term><term>Protéines recombinantes (immunologie)</term><term>Syndrome respiratoire aigu sévère (diagnostic)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines nucléocapside</term><term>Protéines recombinantes</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Nucleocapsid Proteins</term><term>Recombinant Proteins</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate humoral immunity against the SARS-associated coronavirus (SARS-CoV), we studied the profiles of IgG antibodies to the nucleocapsid (N) and spike (S) proteins of SARS-CoV. Serum specimens from 10 SARS patients were analyzed by Western blotting and an enzyme-linked immunosorbent assay (ELISA) using purified recombinant N and truncated S (S1, S2, and S3) proteins as antigens. Western blotting results demonstrated that 100% of the SARS patients tested positive for N protein-specific antibodies, 50% for S1 protein-specific antibodies, 30% for S2 protein-specific antibodies, and 70% for S3 protein-specific antibodies. The ELISA results, which showed positive rates of IgG reactivity against recombinant proteins N, S1, S2, and S3, were, respectively, 28.57, 14.29, 14.29, and 14.29% at week 1, 77.78, 55.56, 44.44, and 66.67% at week 2, 100, 75, 75, and 87.5% at week 3, and 100, 77.78, 77.78, and 88.89% after 3 weeks. The average titers of IgG against recombinant proteins N, S1, S2, and S3 were, respectively, 691, 56, 38, and 84 after 3 weeks. These results suggest that the recombinant proteins N and S3 are potentially useful antigens for a serological diagnosis of SARS. In consideration of possible cross-reactivity among N proteins of SARS-CoV and other coronaviruses, immunoassays using recombinant N protein in combination with S3 as antigens might improve the specificity of SARS diagnoses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16101351</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5498</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>DNA and cell biology</Title><ISOAbbreviation>DNA Cell Biol.</ISOAbbreviation></Journal><ArticleTitle>Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.</ArticleTitle><Pagination><MedlinePgn>521-7</MedlinePgn></Pagination><Abstract><AbstractText>To evaluate humoral immunity against the SARS-associated coronavirus (SARS-CoV), we studied the profiles of IgG antibodies to the nucleocapsid (N) and spike (S) proteins of SARS-CoV. Serum specimens from 10 SARS patients were analyzed by Western blotting and an enzyme-linked immunosorbent assay (ELISA) using purified recombinant N and truncated S (S1, S2, and S3) proteins as antigens. Western blotting results demonstrated that 100% of the SARS patients tested positive for N protein-specific antibodies, 50% for S1 protein-specific antibodies, 30% for S2 protein-specific antibodies, and 70% for S3 protein-specific antibodies. The ELISA results, which showed positive rates of IgG reactivity against recombinant proteins N, S1, S2, and S3, were, respectively, 28.57, 14.29, 14.29, and 14.29% at week 1, 77.78, 55.56, 44.44, and 66.67% at week 2, 100, 75, 75, and 87.5% at week 3, and 100, 77.78, 77.78, and 88.89% after 3 weeks. The average titers of IgG against recombinant proteins N, S1, S2, and S3 were, respectively, 691, 56, 38, and 84 after 3 weeks. These results suggest that the recombinant proteins N and S3 are potentially useful antigens for a serological diagnosis of SARS. In consideration of possible cross-reactivity among N proteins of SARS-CoV and other coronaviruses, immunoassays using recombinant N protein in combination with S3 as antigens might improve the specificity of SARS diagnoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanbin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Zhaorui</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Renquan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Yangong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jianwei</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>DNA Cell Biol</MedlineTA><NlmUniqueID>9004522</NlmUniqueID><ISSNLinking>1044-5498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16101351</ArticleId><ArticleId IdType="doi">10.1089/dna.2005.24.521</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002590 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002590 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16101351
|texte= Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16101351" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |